Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00022035 · ClinicalTrials.gov registry record · NA

Vaccine Therapy in Preventing Flu in Children With Acute Lymphoblastic Leukemia

A NA study of Leukemia and Infection, sponsored by Roswell Park Cancer Institute.

Completed
Registry status
NA
Development phase
2
Study locations

NCT00022035 is a NA study of Leukemia and Infection that has completed, run by Roswell Park Cancer Institute. The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00022035, a NA study of Leukemia and Infection, has completed, sponsored by Roswell Park Cancer Institute.

COMPLETED
Registry status
NA
Development phase
2
Study locations

Study Summary

RATIONALE: Flu vaccine may help the body build an immune response and decrease the occurrence of flu in children who are receiving chemotherapy for acute lymphoblastic leukemia. PURPOSE: Clinical trial to study the effectiveness of vaccine therapy in preventing flu in children who have acute lymphoblastic leukemia.

Conditions Studied

Interventions

  • BIOLOGICAL trivalent influenza vaccine

Study Locations (2)

New Jersey

  • Hackensack University Medical Center - Hackensack

New York

  • Roswell Park Cancer Institute - Buffalo

Trial Details

FieldValue
Start Date 2000-08
Phase NA

Sponsor

Roswell Park Cancer Institute

365 total trials

What the Registry Record Tells You About NCT00022035

The ClinicalTrials.gov registry entry for NCT00022035 describes a study currently listed as completed, categorized as NA. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Leukemia appearing as the primary indexed condition, and to 1 intervention - of which trivalent influenza vaccine is the first listed.

NCT00022035 reports 2 study locations spanning 2 distinct geographic areas - top geographies include New Jersey, New York.

Frequently Asked Questions

What is clinical trial NCT00022035 about?

NCT00022035 is a clinical study titled "Vaccine Therapy in Preventing Flu in Children With Acute Lymphoblastic Leukemia". RATIONALE: Flu vaccine may help the body build an immune response and decrease the occurrence of flu in children who are receiving chemotherapy for acute lymphoblastic leukemia. PURPOSE: Clinical trial to study the effectiveness of vaccine therapy in preventing flu in children who have acute lympho...

What is the current status of trial NCT00022035?

This trial is currently completed. It is a NA study. The study started on 2000-08.

What conditions does trial NCT00022035 study?

This clinical trial studies the following conditions: Leukemia, Infection.

What interventions are being tested in trial NCT00022035?

The interventions under investigation include: trivalent influenza vaccine (BIOLOGICAL).

Who is sponsoring clinical trial NCT00022035?

This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00022035 being conducted?

This trial has 2 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.